Articles Vol. 67 No. CĐ4-HN Ký sinh trùng-HN Hóa sinh 2026 21/04/2026

THE ROLE OF SARCOPENIA INDEX AS A MARKER FOR MUSCULOSKELETAL HEALTH EVALUATION IN TYPE 2 DIABETES PATIENTS

Doan Truc Quynh1,2, Nguyen Thi Le3,4, Le Quoc Tuan3,4
1 School of Medicine, University of Medicine and Pharmacy of Ho Chi Minh City
2 Trường Y, Đại học Y Dược thành phố Hồ Chí Minh
3 Faculty of Medicine, Van Lang University
4 Khoa Y, Trường Đại học Văn Lang
DOI: 10.52163/yhc.v67iCD4.4854
20 Views
8 Downloads
Abstract

Objectives: This study aimed to investigate the association between sarcopenia index and muscle health indicators and to evaluate the incremental value of sarcopenia index in sarcopenia predictive models.

Methods: This cross-sectional study included 74 patients with type 2 diabetes mellitus aged ≥ 50 years who attended the Outpatient Department of the University Medical Center Ho Chi Minh City - Campus 2 from May to October 2025. Sarcopenia was diagnosed using the AWGS (2025) criteria (low ASM/BMI and low handgrip strength). Sarcopenia index was calculated as serum creatinine × eGFRcys, with eGFRcys estimated by the CKD-EPI 2012 cystatin C-based equation. The diagnostic performance of the conventional model (model 1) and the sarcopenia index-augmented model (model 2) was assessed using ROC curves.

Results: The prevalence of sarcopenia and severe sarcopenia was 41.9% and 12.2%, respectively. Sarcopenia index was positively correlated with ASM/BMI (r = 0.38, p < 0.001) and handgrip strength (r = 0.52, p < 0.001). Integrating sarcopenia index significantly improved diagnostic accuracy, with the AUC increasing from 0.8492 (model 1) to 0.8807 (model 2). Sarcopenia index was identified as an independent predictor (OR = 1.06; p = 0.018).

Conclusion: The sarcopenia index is a useful biochemical marker that enhances diagnostic accuracy for sarcopenia when combined with traditional methods. It holds potential as a practical, low-cost screening tool in outpatient settings.

References
[1]
Lee Y.H, Kim J.S, Jung S.W et al. Gait speed and handgrip strength as predictors of all-cause mortality and cardiovascular events in hemodialysis patients. BMC Nephrol, 2020, 21 (1): 166. doi: 10.1186/s12882-020-01831-8 Google Scholar
[2]
Zheng X, Ren X, Jiang M, Han L, Zhong C. Association of sarcopenia with rapid kidney function decline and chronic kidney disease in adults with normal kidney function. British Journal of Nutrition, 2024, 131 (5): 821-828. doi: 10.1017/S0007114523002313 Google Scholar
[3]
Yim J, Son N.H, Kim K.M et al. Establishment of muscle mass-based indications for the cystatin C test in renal function evaluation. Front Med (Lausanne), 2022, 9: 1021936. doi: 10.3389/fmed.2022.1021936 Google Scholar
[4]
Hanna P.E, Ouyang T, Tahir I et al. Sarcopenia, adiposity and large discordance between cystatin C and creatinine‐based estimated glomerular filtration rate in patients with cancer. J Cachexia Sarcopenia Muscle, 2024, 15 (3): 1187-1198. doi: 10.1002/jcsm.13469 Google Scholar
[5]
Lin Y.L, Wang C.H, Chang I.C, Hsu B.G. A novel application of serum creatinine and cystatin C to predict sarcopenia in advanced CKD. Front Nutr, 2022, 9: 828880. doi: 10.3389/fnut.2022.828880 Google Scholar
[6]
Silva-Tinoco R, Castillo-Martínez L, Cabrera-Victoria B et al. Prevalence of diabetes-related sarcopenia and its defining components within primary care: a cross-sectional study. Diabetes Epidemiology and Management, 2025, 18: 100252. doi: 10.1016/j.deman.2025.100252 Google Scholar
[7]
Lin T, Jiang T, Huang X et al. Diagnostic test accuracy of serum creatinine and cystatin C-based index for sarcopenia: a systematic review and meta-analysis. Age Ageing, 2024, 53 (1): afad252. doi: 10.1093/ageing/afad252 Google Scholar
[8]
Tang T, Xie L, Hu S et al. Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer. J Cachexia Sarcopenia Muscle, 2022, 13 (3): 1800-1810. doi: 10.1002/jcsm.12977 Google Scholar